One of India’s pharmaceutical labs has run afoul of the FDA many times this year. The U.S. is dependent on foreign labs like Aurobindo for its drug supply. Can the government help change that?
As 2022 winds down, one thing remains clear, globalization is losing support among policy makers, and even among influencers like Paul Krugman.
The State Department awarded subsidiaries of The Gap in India and Intel in Costa Rica for actions taken by those companies there. Here’s why the parent companies never would have qualified.
Treasury says the dollar is overvalued, but has no plans to fix it. Wall Street will remain the deciding factor in the dollar’s fate. Meanwhile, foreign central banks take action.
China’s Zero Covid protests should persuade Washington, businesses, and consumers that dependence on China for manufacturing American goods will dull the shine off iconic American brands. Political risks are rising.
CPA Committee member Michael Collins looks at what made globalization what it is today and considers the big money barriers to rolling it back.
Senator J.D. Vance of Ohio needs to be on the Senate Finance Committee for the good of the country. Even if Senator McConnell, the top Republican in the Senate, isn’t convinced about the good of the country part, he should see that not assigning Vance to Finance will surely doom Republicans to minority status in…
Most people think that when a drug is recalled by the lab, it is pulled from pharmacy shelves. It’s not. Here’s how drug recalls really work.
Investment managers say they have a fiduciary responsibility to be in China. Here’s why they need to seriously rethink this.
Last week, U.S. Customs and Border Protection’s (CBP) Office of Trade released false government statistics. CBP’s Office of Trade stated that the total value of de minimis shipments fell from $67,039,140,875 in CBP’s FY 2020, down to $39,876,651,152 in FY 2021. These numbers are not accurate, and in fact are certainly a gross, material undervaluation,…